Literature DB >> 17848206

Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.

Tadeusz Krzyszkowski1, Tomasz Dziedzic, Ryszard Czepko, Andrzej Szczudlik.   

Abstract

OBJECTIVE: Glioma cells can produce anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) which inhibit T cell and monocyte function. It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood. The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation). Cytokine concentrations were measured using ELISA methods. RESULTS AND DISCUSSION: There was no difference in serum levels of IL-10 and TGF-beta 2 between groups. Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls. Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848206     DOI: 10.1179/016164107X235149

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  3 in total

1.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

2.  Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Authors:  Tina Verschuere; Matthias Van Woensel; Steffen Fieuws; Florence Lefranc; Veronique Mathieu; Robert Kiss; Stefaan W Van Gool; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2013-07-04       Impact factor: 4.130

3.  Relationship between circulating inflammatory factors and glioma risk and prognosis: A meta-analysis.

Authors:  Yuan Feng; Jia Wang; Dezhong Tan; Peng Cheng; Anhua Wu
Journal:  Cancer Med       Date:  2019-10-09       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.